Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit

Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciproca...

Full description

Bibliographic Details
Main Authors:	Stefano, George B., Mantione, Kirk J., Králíčková, Milena, Ptacek, Radek, Kuzelova, Hana, Esch, Tobias, Kream, Richard M.
Format:	Online
Language:	English
Published:	International Scientific Literature, Inc. 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560700/

id	pubmed-3560700
recordtype	oai_dc
spelling	pubmed-35607002013-04-24 Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit Stefano, George B. Mantione, Kirk J. Králíčková, Milena Ptacek, Radek Kuzelova, Hana Esch, Tobias Kream, Richard M. Review Article Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling in vivo pharmacological model for targeting peripheral sites involved in endogenous morphine expression in human subjects. The biological activities underlying endogenous morphine expression and its interaction with its major precursor dopamine strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD. These critical issues are examined from historical and current perspectives within our short review. International Scientific Literature, Inc. 2012-08-01 /pmc/articles/PMC3560700/ /pubmed/22847214 http://dx.doi.org/10.12659/MSM.883259 Text en © Med Sci Monit, 2012 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Stefano, George B. Mantione, Kirk J. Králíčková, Milena Ptacek, Radek Kuzelova, Hana Esch, Tobias Kream, Richard M.
spellingShingle	Stefano, George B. Mantione, Kirk J. Králíčková, Milena Ptacek, Radek Kuzelova, Hana Esch, Tobias Kream, Richard M. Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
author_facet	Stefano, George B. Mantione, Kirk J. Králíčková, Milena Ptacek, Radek Kuzelova, Hana Esch, Tobias Kream, Richard M.
author_sort	Stefano, George B.
title	Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
title_short	Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
title_full	Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
title_fullStr	Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
title_full_unstemmed	Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
title_sort	parkinson’s disease, l-dopa, and endogenous morphine: a revisit
description	Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling in vivo pharmacological model for targeting peripheral sites involved in endogenous morphine expression in human subjects. The biological activities underlying endogenous morphine expression and its interaction with its major precursor dopamine strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD. These critical issues are examined from historical and current perspectives within our short review.
publisher	International Scientific Literature, Inc.
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560700/
_version_	1611951524821336064

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit

Similar Items